PAYS earnings analysis
What we found in PAYS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Paysign, Inc. reported Q1 2026 revenues of $28.04 million, a substantial 50.8% increase year-over-year, driven by strong growth in pharma and plasma segments. EPS stood at $0.02, slightly below expectations due to increased operating costs. Management remains optimistic about continued growth and has reaffirmed their full year guidance for 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 50.8% YoY
- Total revenue for Q1 2026 was $28.04 million, up from $18.60 million in Q1 2025.
- Strong Performance in Pharma Segment
- Pharma revenue increased 81.9% to $15.68 million, up from $8.62 million.
- Significant Operating Income Improvement
- Income from operations surged 167.9% to $6.67 million compared to $2.49 million.
- Enhanced Gross Margin
- Gross margin improved to 65.0%, up from 62.9% year-over-year.
- Increased Cash Position
- Available cash on hand reached $20.55 million, an increase of $13.70 million from Q1 2025.
- Positive Operating Cash Flow
- Net cash provided by operating activities was $18.79 million, compared to a cash outflow of $6.03 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- EPS Misses Expectations
- Actual EPS was $0.02, below the estimated $0.03.
- Rising Operating Costs
- Operating expenses increased by 25.5%, reaching $11.55 million compared to $9.20 million in the previous year.
- Dependence on Market Conditions
- Continued market pressure may affect operational cost management and revenues from new programs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.02
- Gross margin
- 65.0%
- Operating margin
- 23.8%
- Segment
- Plasma: $11.75M
- Segment
- Pharma: $15.68M
- Segment
- Other: $0.61M
What they said about what is next.
Management reaffirmed full-year 2026 revenue and EPS guidance, citing expected balanced contributions from the plasma and pharma sectors.
The filing reads better than the one before it.
What came before.
- 10-K · March 25, 2026
- Paysign, Inc. demonstrated significant growth in 2025 with total revenues increasing by 40.5% year-over-year, reaching approximately $82 million, driven by expansions in pharma and plasma businesses. The acquisition of…
- 10-Q · November 13, 2025
- Paysign, Inc. reported significant revenue growth of 41.6% year-over-year in Q3 2025, reaching $21.6 million. Both gross and operating margins were slightly lower compared to the previous year, though net income saw a…
- 10-Q · August 6, 2025
- Paysign, Inc. reported strong revenue growth of 33.1% year-over-year in Q2 2025, totaling $19.08 million, driven primarily by a significant increase in pharma revenue. However, diluted EPS decreased to $0.02 from $0.01…
- 10-Q · May 9, 2025
- Paysign, Inc. reported a strong Q1 2025 with total revenues of $18.6 million, up 41.0% year-over-year, driven mainly by a significant increase in pharma revenue. However, the diluted EPS decreased slightly to $0.02…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PAYS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever